These astonishing attributes have served as a basis for the development of a therapeutic adenovirus delivering IL-24 (Ad-IL-24) to cancer patients, a form of treatment that is currently being assessed in clinical trials (Introgen company homepage). This evidence concerns the gene IL24 and cancer.